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Ttrial Fibrillation (AF) and Atrial Flutter (AFL)
n contrast to previous years, when the emphasis was on the
se of ablative therapy for the treatment of atrial fibrillation,
007 has brought about renewed interest in drug-treatment
rials for patients with AF or AFL. The AF-CHF (Atrial
ibrillation in Congestive Heart Failure) trial was reported
t the annual American Heart Association (AHA) meeting
1) and are an important follow-up study to the original
FFIRM (Atrial Fibrillation Follow-up Investigation of
hythm Management) trial (2). In the AFFIRM study of
atients with AF, no benefit was observed for those treated
or rhythm control compared with those treated to achieve
ate control. Atrial fibrillation is common in patients with
ongestive heart failure (CHF) and is said to be an inde-
endent risk factor for cardiac death in some (but not all)
tudies. Hence, the notion that prevention of AF would
enefit patients with CHF would be of great value. The
FFIRM trial contained relatively few patients with con-
estive heart failure, and the AF-CHF trial represents the
rst adequately powered randomized trial of patients with
F and CHF.
The AF-CHF trial was designed as a multicenter, pro-
pective study to determine whether maintenance of sinus
hythm reduced cardiovascular mortality compared with a
ate-controlled strategy in patients with CHF and AF.
econdary pre-specified end points included total mortality,
orsening heart failure, cerebrovascular accident, hospital-
zation, quality of life, and costs. A total of 1,376 patients
ere randomized during the course of a 4-year study period.
nclusion criteria included left ventricular ejection fraction
LVEF) 35% and 1 episode of documented AF within 6
onths of enrollment. Atrial fibrillation was persistent in
9% of patients, and 31% were in New York Heart
ssociation (NYHA) functional class III to IV. Patients
ere randomized to a rhythm-controlled arm and were
reated with amiodarone as the initial drug choice and
otalol or dofetilide were used in selected cases. Repeated
irect current cardioversions were used to maintain sinus
rom *Cardiac Electrophysiology, University of California San Francisco, andq
Veterans Affairs Medical Center, San Francisco, California.
Manuscript received February 12, 2008; accepted February 22, 2008.hythm. The rate control group was treated with digoxin
nd beta-blockers. Both groups received optimal medical
anagement for heart failure, and both groups received
nticoagulant therapy. The prevalence of sinus rhythm on
ollow-up examination was approximately 80% in the
hythm-controlled group. No significant difference was
ound in the primary outcome between the rhythm-
ontrolled group versus the rate-controlled group (26.7% vs.
5.5%). Similarly, there was no difference in total mortality
31.8% vs. 32.9%), stroke (2.6% vs. 3.0%), or worsening
eart failure (27.6% vs. 30.8%). The authors concluded that
rhythm control does not improve cardiovascular mortality
hen compared to rate control.” The results of the AF-
HF trials, therefore, extend the original observation of the
FFIRM trials to those with AF and CHF. There appears
o be no overriding need to maintain sinus rhythm in this
ubgroup as long as rate control is achieved.
In addition, several large drug trials were reported. For
xample, 2 large-scale trials of dronedarone (a homolog of
miodarone) for patients with AF or AFL were reported
3). The 2 studies had identical protocols, but one was
onducted in Europe whereas the other was in non-
uropean countries. The study protocol involved a multi-
enter, double-blind, placebo-controlled study for patients
ith paroxysmal AF or AFL but without evidence of class
II or IV CHF. In both trials, the median time to arrhyth-
ia recurrence was significantly greater for the treated
roups (41 days vs. 96 days for the European group and 59
ays vs. 158 days for the non-Europeans). Of further
nterest was the fact that there was no difference in the
ncidence of adverse side effects between the treated and
lacebo groups apart from a greater incidence of increased
erum creatinine for the treated group. A previous trial that
sed dronedarone for patients with congestive heart failure
ANDROMEDA [Antiarrhythmic Trial with Dronedar-
ne in Moderate-to-Severe Congestive Heart Failure Eval-
ating Morbidity Decrease] trial) was terminated prema-
urely because of increased mortality in the treated group.
he current study did not address this important issue. In
ddition, we do not have a head-to-head comparison
etween this agent and amiodarone for this patient cohort.
he lack of reported toxicity with respect to dronedarone is
uite impressive.
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f several recent reports. Earlier trials of this agent assessing
afety and efficacy (ACT [Atrial arrhythmia Conversion
rial] 1 and ACT 3]) (4) included a total of 575 patients.
he overall conversion rates in response to intravenous
ernakalant for those with recent-onset AF (3 h to 7 days)
as 51.1% versus 38% for placebo (p  0.0001). The
edian time to conversion ranged from 10 to 11 min. Stiell
t al. (5) reported on the safety and efficacy of a recent
pen-labeled multicenter trial (ACT 4). This trial involved
36 patients of AF of3 h duration. Of this group, 167 had
F of 7 days’ duration. Of the patients with recent-onset
F (7 days), 51% converted to sinus rhythm within a
edian time of 14 min. The conversion rate for those with
F of 8 days or longer was10%. There were no reports of
entricular fibrillation or torsades in any of the reported
ernakalant trials; however, nonsustained ventricular tachy-
ardia (VT) was reported in 3.4% of patients within 2 h and
n 6.4% at 2 to 24 h. A recent report of the AHA meeting
lso documented the safety and efficacy of intravenous
ernakalant for patients with post-surgical AF (6).
The available data suggest that the intravenous form of
ernakalant will be a welcome addition for treatment of
atients with AF. Its mode of action appears unique in that
t inhibits both the atrial ultra-rapid K current as well as
requency-dependent Na channels. Although its efficacy is
imilar to that of ibutilide, the safety profile appears to be
uperior. An oral preparation of vernakalant is in the early
tages of study.
A recent prospective randomized study by Kafkas et al.
7) compared rates of conversion with sinus rhythm for
hose with recent-onset AF and AFL treated with either
ntravenous amiodarone versus intravenous ibutilide. For
atients with either AF or AFL, intravenous ibutilide was
ignificantly superior to amiodarone in conversion to sinus
hythm. This study is a potentially important one in view
f the somewhat-puzzling popularity in use of intrave-
ous amiodarone for acute management of patients with AF
r AFL.
Researchers of a randomized prospective study (8) com-
ared the use of oral amiodarone versus cavotricuspid
blation for patients with a first onset of AFL. The study
omprised 104 patients randomized to the 2 treatment
rms. The patients treated with ablation achieved signifi-
antly better success in terms of maintenance of sinus
hythm. This study extends previous observations favoring
blative therapy and extends these observations in support
or early superiority of ablative treatment.
Azimilide is an experimental agent with properties that
lock the late outward K currents (Ikr and Iks blockade).
revious studies have shown that the use of azimilide may
e effective in the maintenance of sinus rhythm after
ardioversion (9). In a recent oral azimilide trial, 402
atients with AF/AFL (and 56 with paroxysmal supraven-
ricular tachycardia) were enrolled (10). The authors found
o significant difference in time to first recurrence between freated patients (38 days) and the placebo group (27 days).
f note was the occurrence of nonsustained VT (1 episode
f torsades) in 4 patients, all in the treated group. The study
uggests that oral azimilide would appear to have no role in
he management of patients with AF, AFL, or paroxysmal
upraventricular tachycardia.
entricular Arrhythmias
he ABCD (Alternans Before Cardioverter Defibrillator)
rial. The authors of early primary prevention trials used
nvasive electrophysiological (EP) testing to identify high-
isk individuals (11,12). This approach resulted in excellent
herapeutic efficacy (4 implantable cardioverter-defibrillators
ICDs] for each life saved) (13). More recent trials were
onstructed to avoid the need for invasive testing and
ssessed risk on the basis of reduced left ventricular ejection
raction (14,15). On the basis of these studies, patients with
n ejection fraction (EF) of 35% were found to benefit
rom ICDs. Unfortunately, this approach required insertion
f 15 to 17 ICDs to save one life. The rationale behind the
BCD trial (which was first reported at the AHA meeting
n 2006) was to compare the relative efficacy of invasive EP
esting with noninvasive microvolt alternans testing. The
atter is a noninvasive spectral approach to assess very small
microvolt) beat-to-beat alternans of the T waves. Previous
tudies emphasized the powerful negative predictive accu-
acy of microvolt T-wave alternans (MTWA) therapy
16,17).
A total of 566 patients were enrolled from 43 centers.
nclusion characteristics were the presence of coronary
rtery disease, LVEF 40%, and nonsustained VT (3
eats). The study was powered to test the hypothesis that
TWA was noninferior to invasive EP testing in predict-
ng events at 1 year. The study group consisted of 84% men,
verage age 65  10 years with a mean LVEF of 0.28 
.08. The MTWA was positive in 46%, negative in 29%,
nd indeterminate in 23%. The EP study was positive in
9% and negative in 61%. However, discordant results were
ound in 55% (i.e., MTWA, EP, or vice versa). A total
f 65 patients met the end point of VT, ventricular
brillation, or sudden cardiac death (10 patients).
Despite the discordant results, there was no difference in
ither the positive or negative predictive accuracy comparing
P-guided versus MTWA-guided therapy. The latter was
efined by an indeterminate MTWA and  EP study. Of
nterest was the finding that Kaplan-Meier event rates
omparing EP versus EP groups remained significantly
ifferent for up to 2 years of follow-up, whereas MTWA-
irected therapy proved predictive for only the first year.
hey found a synergistic relationship between EP and
TWA testing. The predicted event rate was markedly
mproved (12.6%) when both tests are positive and quite low
2%) when both are negative or normal. The therapeutic
fficacy (appropriate shock) of implanting ICDs improved
rom 7% (using LVEF alone) to 66% in those with a
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ality alone improves efficacy to 35%.
The authors concluded that in patients with coronary
rtery disease, nonsustained VT, and LVEF35% MTWA
s as effective as EP for prediction of events at 1 year. They
ound that the combination of MTWA and EP was
ynergistic in predicting outcome; however, the predictive
alue of MTWA is dissipated in the second year of
ollow-up. In contrast, Bartone et al. (18) found that a
on-negative MTWA test proved to be a robust predictor
f all-cause mortality for those with ischemic disease with a
6-month follow-up.
This represents an important prospective study because
hey were able to compare invasive with non-invasive
esting. The negative predictive value of MTWA was
upported but the positive predictive accuracy was quite
oor (Fig. 2). What are the practical implications for the
linicians? A negative test tilts toward not inserting the
efibrillator but at the expense of missing a small percentage
f patients who might benefit. In addition, the data empha-
ize the rationale for the MTWA-directed approach (i.e.,
TWA indeterminate EP). No technique is perfect, and
he ultimate use will be dependent on the clinical decision of
he acceptable threshold for which patients should be
reated. This, of course, is taking into account the impor-
ance of age and comorbidities.
Another recent trial that focused on the use of MTWA
as presented at the annual American College of Cardiol-
gy meeting (19). This trial attempted to test whether
bnormal MTWA predicts life-threatening arrhythmias in
MADIT (Multicenter Automatic Defibrillator Implant
rial)-II population. The study included 575 patients with
prior myocardial infarction and EF 30%, and the
rimary end points were appropriate ICD shocks or ar-
hythmic deaths. The population showed a mean EF of
4%, and most had a history of congestive heart failure.
here was no significant difference in end points between
he MTWA negative patients (10%) versus those with
on-negative (positive and indeterminate) (13%). Further-
ore, sub-group analyses showed that those patients with
RS120 ms were at low risk regardless of MTWA result.
lthough the methodology and patient population of the
ASTER trial differed from the ABCD trial it, neverthe-
ess, suggests caution in the use of MTWA as a risk
tratifier. In addition, a very thoughtful and critical appraisal
f MTWA was recently published (20). They concluded
hat “the evidence for the use of MTWA in risk stratifica-
ion of SCD is compelling in some aspects, principally its
PV [negative predictive value] in patients with ischemic
VSD [left ventricular systolic dysfunction]. However, the
vailable evidence is not yet sufficient to allow its extrapo-
ation to routine clinical use in large numbers of patients to
etermine whether primary prevention ICD implantation is
ndicated.”
Another interesting report involved a study of ranolazinen patients with acute coronary ischemia (21). Ranolazine is gdrug that was recently approved for management of
atients with angina pectoris that is refractory to conven-
ional therapy. The mechanism of the anti-ischemic action
s not clear, but the effects of this drug on ion channel
unction have been clarified. Ranolazine has been found to
e associated with mild prolongation of the QT interval.
lectrophysiological studies have shown that ranolazine acts
o block the late Na current (which would tend to shorten
he QT) and to block Ikr current (which would tend to
rolong the action potential duration and QT). The Ikr
ffect appears to predominate because the drug is associated
ith a mild QT prolonging effect. Furthermore, the effects
n the Ikr current appear to predominate in epicardial and
ndocardial cells, whereas the Ina block predominates in
id-myocardial cells. Overall, the drug appears to decrease
ransmembrane repolarization heterogeneity. Blockage of
he late Ina current would be expected to prevent systolic
a2 overload and might have antiarrhythmic properties.
his reasoning was the underpinning for a recent trial,
hich randomized 6,560 patients with non–ST-segment
levation myocardial infarction acute coronary syndrome to
eceive either ranolazine or placebo (22). The patients
nderwent continuous electrocardiogram monitoring for 7
ays after enrollment. A pre-specified set of arrhythmias
as examined in blinded fashion by the Core lab. The major
ndings were a statistically significant decrease in the
ncidence of nonsustained VT lasting either 4 or 8 beats. For
hose treated with ranolazine, there was no difference in the
ncidence of sustained polymorphous VT compared with
hose treated with active drug (0.32%) versus placebo
0.22%; p  0.46). The episodes of polymorphous VT
ppeared to be related to myocardial ischemia in both
roups. There was no significant difference in either total
ortality or in sudden death between groups. This was
rue even for those in the highest risk groups (i.e., CHF,
evere ischemia). In addition, although the incidence of
F was less for the treated group, this was not statisti-
ally significant.
In summary, although the apparent finding of an antiar-
hythmic effect is of interest, this alone is of limited practical
alue. The lessons learned from CAST (Cardiac Arrhyth-
ia Suppression Trial) are evident. A drug that decreases
remature ventricular complex density does not necessarily
rolong life. The neutral effect of the drug on overall
ortality is a testament to its safety. Its true role as an
ntiarrhythmic agent remains to be established.
ardiac Genetic Syndromes
ome of the most striking advances in clinical cardiac EP
ontinue to occur in the area of the genetic arrhythmia
yndromes. In 2007, there was a spate of excellent basic and
linical studies further elucidating the long-QT syndrome
LQTS). The latter has occurred because of the fact that
0% to 80% of these patients may now be successfully
enotyped and because of the availability of a large inter-
n
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Year in Clinical Cardiac Electrophysiology May 27, 2008:2075–81ational registry for long-QT patients (23) allowing for
henotype-genotype correlations.
QTS. This syndrome was first described in 1957 by
ervell and Lange-Nielsen (24) and highlighted the associ-
tion between congenital deafness, prolonged QT interval,
nd sudden death. It has been determined that gain of
unction of Na channels (encoded by SCN5A) or decrease
n function of the delayed k rectifier currents Iks (slow
ctivation K current) or Ikr (rapidly activated k current)
re the main causes of the LQTS. The mutations involve
ither the membrane-spanning  subunits or the associated
roteins attached to these channels. The vast majority of
atients will have genetic abnormalities involving k chan-
els (Iks–LQT1), (Ikr–LQT2), or Na channels SCN5A
LQT3) (25). Rare mutations of a gene encoding the L-type
a2 channel have been described.
The vast majority of known mutations involve genes that
ncode Iks and Ikr channels (85%), whereas SCN5A
utations make up approximately 13%. Compound muta-
ions in the same or different genes occur in as many as 10%
f genotype positive groups (26) and appear to be associated
ith a greater incidence of arrhythmias. A host of recent
tudies have focused on the ungenotyped 25% to 30% of
QTS patients (27–30). These studies have focused on
ntron mutations or abnormalities in the exon splice sites. In
ddition, 2 newer mutations causing the LQT1 syndrome
ave been described, one involving the Yotiao protein
omplex (31), which produces a pattern similiar to LQT1
Iks current), and the other resulting in an abnormality of
lpha-1-syntrophin, which produces a LQT3 picture (32).
ewer clinical findings. A number of studies have focused
n genotype-phenotype interactions. For example, in LQT2
atients, mutations in the pore region of the KCNH2 gene
re at increased risk for cardiac arrhythmias compared with
hose with nonpure mutations (33). One study focused on
QT patients between the ages of 18 and 40 years and
ound that female gender, LQT2, QTc 500 ms, and the
resence of cardiac events (syncope, aborted sudden death)
efore the age of 18 years were associated with an increased
isk of cardiac events in adulthood (34). In contrast, male
dolescents between the ages of 10 and 12 years were at
reater risk than female adolescents. Similarly, QTc dura-
ion and syncopal episodes were found to be risk factors for
ife-threatening events (35).
The beneficial effects of beta-blocker therapy have long
een appreciated. More recent observations have focused on
he fact the most pronounced beneficial effects are observed
or those with LQT1 with decreased efficacy for those with
QT2 and especially for those with LQT3 or the Jervell-
ange-Nielsen syndrome (36), Another study focused on
he effects of pregnancy on women with LQTc (37). It was
ound that the risk for cardiac events was reduced during
regnancy but that the 9-month post-partum period was
dentified as a high-risk period. However, treatment with
eta-blockers mitigated the post-partum risk. pA recent study focused on a cohort of 27 children with
QTS who were treated with a defibrillator (38). Most of
hese patients were genotyped as LQT2 or LQT3 and
nderwent implantation after failed beta-blocker therapy.
n follow-up, 5 (12%) had appropriate shocks and 4 had at
east 1 inappropriate shock. None had recurrent shocks
electrical storm). This study highlights the emerging expe-
ience of automatic ICD therapy in the high-risk pediatric
opulation. It is important to set the automatic ICD
ischarge rate at appropriate levels for active children to
void inappropriate shocks incident to sinus tachycardia.
Finally, important insights were gained from a retrospec-
ive study in which the authors used post-mortem genetic
esting on young individuals with sudden unexplained
eath. A total of 17 genetic mutations were found in 49
ubjects studied (39). Ten were found to have abnormalities
n genes associated with LQTS, and 7 had abnormalities in
he RyR2 genes responsible for the syndrome of cat-
cholaminergic polymorphous ventricular tachycardia. Ad-
itional studies have shown that the LQTS is implicated in
% to 10% of infants with sudden infant death syndrome
40–42) or in stillbirth children (43).
ardiac Rhythm and Heart
ailure Management Devices
riving with ICD. Patients with ICDs often ask their
hysicians whether they can continue driving. Despite
ecent guidelines that suggest resumption of driving as soon
s the surgical incision is healed, it remains a difficult and
ncomfortable question because of patient and public safety
oncerns, impact on quality of life, and socioeconomic and
egal ramifications. Recently, the TOVA (Triggers of Ven-
ricular Arrhythmias) study provided some reassuring infor-
ation on this matter when the investigators examined the
mpact of driving on ICD discharges among 1,188 ICD
atients with class I and II implant indications (44). The
elative risk of shocks for VT/ventricular fibrillation was
nly significantly increased during the 30-min period after
riving. Most importantly, the risk of ICD shock was not
reater during driving. Neither new implants (defined as6
onths implanted) nor indications (primary or secondary
revention) had an interactive effect on the analysis. The
tudy also pointed out that 1 in 7 patients experiencing
shock actually had an auto accident. Precise guidelines
or driving for patients with ICDs have been previously
ublished (45).
ardiac resynchronization therapy (CRT). The investi-
ators of the COMPANION (Comparison of Medical
herapy, Pacing and Defibrillation in Heart Failure) study
erformed a retrospective data analysis to determine
hether class IV patients would benefit from cardiac resyn-
hronization therapy with defibrillator (CRT-D, n 83) or
ithout defibrillator (CRT, n  79) when compared with
atients on optimal medical therapy (OPT, n  55) (46).
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May 27, 2008:2075–81 Year in Clinical Cardiac Electrophysiologyhe studied patients had a very poor prognosis, as evidenced
y a 44% mortality at the end of 1 year in the OPT group.
At 2 years, when compared with OPT, both CRT and
RT-D improved: 1) the time to all-cause mortality or first
ospitalization, and 2) the time to all death or heart failure
ospitalization. Only CRT-D benefited the time to sudden
eath: 25%, 16%, and 9% died of sudden cardiac death in
ear 2 for OPT, CRT, and CRT-D, respectively. The result
uggested that CRT and CRT-D should be considered in
mbulatory NYHA functional class IV patients with heart
ailure. The data confirmed once again that the ICD is
ffective in preventing sudden cardiac arrhythmic death even
n NYHA functional class IV patients. As therapy devices
or patients with severe heart failure, neither CRT nor
RT-D improved the time to heart failure death. It is
lausible that the ventricles were too sick to allow for
mprovement in mechanical performance.
Results from small and nonrandomized studies have
uggested that CRT may benefit patients with left ventric-
lar mechanical dyssynchrony even in the presence of
ormal QRS duration. This unsettled issue was examined in
randomized nonblinded study (RethinQ: the Cardiac
esynchronization Therapy in Patients with Heart Failure
nd Narrow QRS) involving 172 patients with NYHA
unctional class III heart failure, an EF of 0.35, QRS
uration of 130 ms, and ventricular dyssynchrony docu-
ented by tissue Doppler (47). One-half of the patients
eceived a CRT-D and the other half received an ICD. At
months, there were no differences between the 2 groups in
eak oxygen consumption, quality-of-life score, 6-min walk
istance, and heart failure events requiring intravenous
herapy. On the basis of these results, it was concluded that
atients with heart failure and narrow QRS interval may not
enefit from CRT. It remains to be seen whether this study
efines the role of CRT in patients with narrow QRS
omplex. It is conceivable that the negative results were
elated to the short follow-up period and the identification
ethod (M-mode echocardiography was not used in 96% of
he patients). The study was not designed to examine common
nd points such as mortality and heart failure hospitalization.
CD patients and risk stratification. On the basis of a
umber of multicenter clinical studies, ICD implant indi-
ations have been greatly expanded since their introduction.
t the same time, we have been trying to refine our patient
election criteria with the ultimate goal of implanting ICD
nly in patients who will need therapy. The MUSTT
Multicenter Unsustained Tachycardia Trial) investigators
etrospectively examined their database to construct a risk-
tratification model to better predict mortality risk and sudden
eath in patients with coronary artery disease, LVEF 0.40,
onsustained VT, and inducible ventricular sustained VT,
ith the goal of improving ICD patient selection (48).
The following risk factors were found to have a statisti-
ally significant association with total mortality: NYHA
unctional class at the time of enrollment, left bundle branch
lock or interventricular conduction delay, history of heart tailure, LVEF, age, atrial fibrillation at the time of enroll-
ent, inducible VT, and previous coronary artery bypass
rafting. Arrhythmic death was associated with left bundle
ranch block or interventricular conduction delay, heart
ailure, LVEF, inducible VT, nonsustained VT 10 days
eyond coronary artery bypass grafting, and patients en-
olled into the study as inpatient. Using patient survival data
n the MUSTT database and assigning points to each risk
actor, a model was created to best predict the survival of
atients in the MUSTT database.
As pointed out by the accompanying editorial, the use of
his risk-stratification model is severely limited by the fact
hat it is based on patients who had inducible VT by EP
tudy, an approach that is rarely used in clinical practice
49). Renal function, which had been identified as an
ndependent predictor of mortality, was not found to be a
isk factor in the analysis (50). Nevertheless, the model
howed that several other variables carried a similar prog-
ostic significance as LVEF: in the absence of other risk
actors, an LVEF 0.30 was associated with a 2-year total
ortality of only 5%.
Analysis of patients in the conventional therapy arm of
ADIT-II identified 5 risk factors in predicting all-cause
ortality: 1) New York Heart Association functional class
II; 2) age 70 years; 3) blood urea nitrogen 26 mg/dl;
) QRS duration 0.12 s; and 5) AF (51). The use of ICD
herapy reduced 2-year mortality by 49% among patients
ith 1 risk factor and offered no benefit in patients with
o risk factor (approximately one-third of the patients,
-year mortality of only 8%) and with marked renal
ysfunction (blood urea nitrogen 50 mg/dl and/or
reatinine 2.5 mg/dl). Similar to the MUSTT analysis,
he investigators observed that LVEF may not be the
nly selection criterion for ICD therapy in patients with
schemic cardiomyopathy.
rouble with high-voltage (HV) ICD leads. The reliabil-
ty of HV defibrillator leads was called to attention by a
erformance report on 990 leads implanted between 1992 to
005 from a single registry (52). The survival rate was
isturbingly low: 90%, 85%, and 60% at 3, 4, and 8 years,
espectively. The failure rate increased progressively with
ime. The adverse events included insulation defects (56%),
ead fractures (12%), loss of ventricular capture (11%),
bnormal lead impedance (10%), and sensing failure (10%).
t is important to note that two-thirds of lead defects could
e detected by routine device interrogation, underscoring
he importance of post-implant device follow-up. The
ailure rate may be overestimated because the analysis
ncluded complications (such as T-wave oversensing, exit
lock, and R-wave under-sensing) that may not always
elate to intrinsic lead defects. This report was soon fol-
owed by a major Food and Drug Administration class I
ecall of the Medtronic Fidelis (Medtronic, Minneapolis,
innesota) leads and reports on a still unsettled complica-
ion in another HV lead family.
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Year in Clinical Cardiac Electrophysiology May 27, 2008:2075–81Hauser et al. (53) reported a greater-than-expected rate of
ailure in the Medtronic Sprint Fidelis model 6949 HV lead.
ix of 583 Medtronic Sprint Fidelis model 6949 implanted
etween September 2004 and February 2007 failed over the
ourse of 31 months (96% survival at 33 months). Only 1 of
85 Medtronic Sprint Quattro model 6847 failed over the
ourse of 65 months (approximately 99% survival at 65
onths). Analysis of the Food and Drug Administration
anufacturers User Facility Device Experience database and a
eview of the manufacturer’s analyses showed that the most
requently reported defects for the Sprint Fidelis HV leads
ere fracture of the pace-sense conductor or coil and the HV
onductor, leading to high impedances, noncapture, and inap-
ropriate shocks (in response to nonphysiological noises).
ecause both the Sprint Fidelis and the Sprint Quattro leads
sed the same materials and construction, the cause for the
igh failure rate was postulated to be the small diameter (6.3 F)
f the Sprint Fidelis lead, which lowered the conductors’
olerance to physical stress. In October 2007, Medtronic
nnounced that the Sprint Fidelis lead had been withdrawn
rom the market and the U.S. Food and Drug Administration
laced these leads (268,000 leads implanted worldwide) in a
lass I recall. Medtronic analyses confirmed that the root cause
as lead fracture and reported a 30-month survival rate of
7.7% for the Fidelis leads, compared with 99.4% for the larger
print Quattro leads (54).
Meanwhile, an entirely different potential complication
onfronts another HV lead. In a single-center, retrospective
nalysis of 2 families of HV leads (Riata 1580/1581 and
590/1591, St. Jude Medical, Sylmar, California and Sprint
idelis 6949, Medtronic), the investigators observed a
ignificantly greater incidence of subacute lead perforation
1 to 10 days post-implant) with the Riata leads as com-
ared with the Sprint Fidelis leads (55). Five perforations
ccurred in 120 Riata leads, whereas none occurred in 111
print Fidelis leads.
However, the safety issue associated with the Riata leads
r any small-diameter leads has yet to be established. The
maller lead diameter cannot be the root cause of the
erforation problem because the Medtronic Sprint Fidelis
eads have similar size. Lead perforation is a recognized
otential complication of implantation (0.1% to 0.8% for
acemaker leads and 0.6% to 5.2% for ICD leads) (56). It
as been usually attributed to patients’ medical conditions
nd to implant techniques, especially when the data were
rom a single center. However, since the publication of this
eport, several case reports describing acute and delayed
30 days) perforation with the small-diameter Riata HV
eads have been published (57–59). On the other hand,
nalyses performed by researchers at the St. Jude Medical
ardiac Rhythm Management Division do not suggest a
reater incidence of perforation (60). Verbal and written
ncidence reports and returned product analysis showed
erforation rates of 0.057% for 86,000 Riata 8-F leads and
.157% for 35,000 implanted 7-F leads. The overall perfo-
ation rate for the Riata leads was 0.33% to 0.34% in 2
1egistries administered by researchers from the St. Jude
edical Cardiac Rhythm Management Division (ACT and
PTIMUM). At this point, more data from multiple
ources will be needed before we can definitively identify if
hese leads are indeed unsafe.
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